P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses The Breakthrough Oncology Accelerator flagship program.

Origin is one of the founding members of The Breakthrough Oncology Accelerator flagship program, notes Smith. Their role is in building and growing the financial components of the partnership with Atlantic Health and Translational Genomics Research Institute (TGen). By creating and financing new payment models, more patients will be able to access novel therapies moving forward, explains Smith.

Origin identifies as a global partner to Atlantic Health and TGen, adds Smith. By overseeing the business and financial strategies of the partnership, Origin hopes to expand their ability to bring novel therapies to patients, aid in identifying the right patients to receive the right therapies, and create new monitoring programs that work best in real time to ensure the deliverance of those therapies.

Videos

Cosmo Smith on The Breakthrough Oncology Accelerator Flagship Program

P. Cosmo Smith, managing partner, Origin Commercial Ventures, discusses how Origin improves patient access in oncology.

Patients go to health systems for access to novel therapeutics, explains Smith, which is why Origin decided to partner with Atlantic Health. As Origin moves forward, they hope to embody a similar culture as that of Atlantic Health by providing access to the therapies that have the best chance of success to the greatest number of patients, says Smith.

Enabling that success is not an insignificant barrier, explains Smith. There needs to be a level of both excitement within the parent institutions as well as financial creativity. One of the missions at Atlantic Health is to create better therapeutic access to patients by looking at new insurance and payer structures. This is where Origin comes in, as they are heavily involved in those regards on an industry-wide basis. The goal, says Smith, is to have a variety of available health plans and carve out programs that allow patients access to the treatment they need when they need it.

Cosmo Smith on How Origin Improves Patient Access

P. Cosmo Smith, managing partner, Origin Commercial Ventures, discusses the difference between clinical liquidity and financial liquidity.

The Breakthrough Oncology Accelerator flagship program at Atlantic Health System was announced on October 4, 2018, of which the Translational Genomics Research Institute and Origin Commercial Ventures will be a part.

Smith, who is responsible for strategy and business development at Origin, says that financial liquidity is critical in unleashing clinical liquidity. Smith says that Origin is working very closely with the payer community, pharmaceutical companies, and the reinsurance and banking communities to create more shared performance models with payers.

This will help streamline the coordination that is required to bring novel therapies to patients, notes Smith. Now, Origin is in the process of building financial models that will enable a longer stream of payments, more performance-based payments, and more coordinated protocols and therapies between payers and clinicians. This will ensure that patients receive the therapy when they need it, practical onboarding of novel therapies, and incentive to pharmaceutical companies to bring more therapies to the table.

P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses the difference between clinical liquidity and financial liquidity.

P. Cosmo Smith, MBA

Articles

Cosmo Smith on The Breakthrough Oncology Accelerator Flagship Program

Cosmo Smith on How Origin Improves Patient Access

Cosmo Smith on the Difference Between Clinical Liquidity and Financial Liquidity